Business Context and Reporting Period
Imunon, Inc. (IMNN) filed a Form 8-K Current Report on March 23, 2026. The filing addresses a capital raise event under an existing "At the Market" (ATM) offering program.
Key Financial Metrics
This filing does not report operational financial metrics such as revenue, profit, cash flow, or margins. The primary financial data relates to the equity offering program:
- Additional Registration: $7,000,000 of common stock shares registered via a prospectus supplement.
- Total Program Capacity: $17,000,000 (aggregate of previous and new registration).
- Amount Sold to Date: $4,797,848 of shares sold under the Sales Agreement prior to this filing.
- Remaining Capacity: Approximately $12,202,152 available for future sales under the current agreement.
Material Changes
The material change reported is the expansion of the Company's registered share capacity under its Sales Agreement with H.C. Wainwright & Co., LLC. The Company previously registered up to $10,000,000; this filing increases the total registered amount to $17,000,000.
Guidance, Outlook, and Risks
The filing contains no management guidance, financial outlook, or discussion of operational risks. The transaction is executed pursuant to the Sales Agreement dated May 25, 2022, as amended on May 15, 2024. The filing includes a legal opinion regarding the legality of the shares (Exhibit 5.1).
Investor Verification Checklist
- Verify the current share price and potential dilution impact of the remaining $12.2 million in ATM capacity.
- Review the full Sales Agreement (Exhibit 10.1 in prior filings) for commission rates and termination clauses.
- Confirm the Company's current cash position and burn rate to assess the necessity of this capital raise.
- Check for any concurrent filings regarding the use of proceeds from the $4.8 million already sold.